



**Impact of cationic substituents in phenalen-1-one photosensitizers on antimicrobial photodynamic efficacy**

Journal:	<i>Photochemical &amp; Photobiological Sciences</i>
Manuscript ID	PP-ART-07-2015-000262.R2
Article Type:	Paper
Date Submitted by the Author:	09-Nov-2015
Complete List of Authors:	<p>Tabenksi, Isabelle; University Medical Center Regensburg, Department of Conservative Dentistry and Periodontology            Cieplik, Fabian; University Medical Center Regensburg, Department of Conservative Dentistry and Periodontology            Tabenksi, Laura; University Medical Center Regensburg, Department of Conservative Dentistry and Periodontology            Regensburger, Johannes; University of Regensburg, Department of Dermatology            Hiller, Karl-Anton; University Medical Center Regensburg, Department of Conservative Dentistry and Periodontology            Buchalla, Wolfgang; University Medical Center Regensburg, Department of Conservative Dentistry and Periodontology            Maisch, Tim; University of Regensburg, Department of Dermatology            Spaeth, Andreas; University of Regensburg, Department of Organic Chemistry</p>

1                   **Impact of cationic substituents in**  
2                   **phenalen-1-one photosensitizers on**  
3                   **antimicrobial photodynamic efficacy**

4

5 Isabelle Tabenski<sup>1</sup>, Fabian Cieplik<sup>1</sup>, Laura Tabenski<sup>1</sup>, Johannes Regensburger<sup>2</sup>,  
6 Karl-Anton Hiller<sup>1</sup>, Wolfgang Buchalla<sup>1</sup>, Tim Maisch<sup>2#\*</sup> and Andreas Späth<sup>3#\*</sup>

7

8 <sup>1</sup> Department of Conservative Dentistry and Periodontology, University Medical  
9 Center Regensburg, Regensburg, Germany

10 <sup>2</sup> Department of Dermatology, University Medical Center Regensburg, Regensburg,  
11 Germany

12 <sup>3</sup> Department of Organic Chemistry, University of Regensburg, Regensburg,  
13 Germany

14

15

16 \* Corresponding authors:

17 [tim.maisch@ukr.de](mailto:tim.maisch@ukr.de) (TM)

18 [andreas.spaeth@chemie.uni-regensburg.de](mailto:andreas.spaeth@chemie.uni-regensburg.de) (AS)

19

20

21 # These authors share senior-authorship.

22

23 **Key words**

24 antimicrobial

25 photodynamic

26 phenalen-1-one

27 guanidinium

28 SAGUA

29 cationic photosensitizer

## 30 **Abstract**

31 Light-mediated killing of pathogens by cationic photosensitizers (PS) is a promising  
32 antimicrobial approach avoiding resistances as being present upon antibiotics. In this  
33 study we focused on the impact of the substituents in phenalen-1-one PS.  
34 Photodynamic efficacy depending on positively charged moieties including a primary  
35 aliphatic, quaternary aliphatic, aromatic ammonium and a guanidinium cation was  
36 investigated against Gram-positive and Gram-negative pathogens. Considering the  
37 altered steric demand and lipophilicity of these functional groups we deduced a  
38 structure activity relationship.

39 SAGUA was the most potent PS in this series reaching a maximum efficacy of  $\geq 6$   
40  $\log_{10}$  steps of bacteria killing at a concentration of 10  $\mu\text{M}$  upon irradiation with blue  
41 light (20  $\text{mW}/\text{cm}^2$ ) for 60 s (1.2  $\text{J}/\text{cm}^2$ ) without exhibiting inherent dark toxicity. Its  
42 guanidinium moiety may be able to form strong bidentate and directional hydrogen  
43 bonds to carboxylate groups of bacterial surfaces in addition to ionic charge  
44 attraction. This may supplement fast and effective antimicrobial activity.

## 45 Introduction

46 The discovery of antibiotics can be seen as one of the most important breakthroughs  
47 in medical history. Antibiotics have revolutionized the way patients with bacterial  
48 infections are treated and have contributed to reducing the mortality and morbidity  
49 from bacterial diseases. However, unconsidered and abundant use in human as well  
50 as in veterinary medicine and animal fattening finally contributed to the emergence of  
51 antibiotic-resistant strains, e.g. methicillin-resistant *Staphylococcus aureus* (MRSA)  
52 or vancomycin-resistant *Enterococci* (VRE) strains <sup>1</sup>. Furthermore, resistances  
53 against antiseptical and antimicrobial agents, which are clinically used, e.g.  
54 chlorhexidine <sup>2</sup> and triclosan <sup>3</sup>, are arising. The worldwide spread of resistances  
55 among pathogens represents an immense problem for public health <sup>1</sup>.

56 Consequently, the demand for developing alternative approaches for successful  
57 inactivation of pathogens is becoming more and more crucial. These alternative  
58 approaches should operate – different from antibiotics – not towards one specific  
59 target according to the so-called key-hole-principle, but as multi-target processes, in  
60 order to avoid development of resistances in microorganisms <sup>4,5</sup>.

61 A promising approach meeting these requirements may be the antimicrobial  
62 photodynamic therapy (aPDT), which kills bacteria via an oxidative burst by causing  
63 damage to cellular structures and biomolecules <sup>6,7</sup>. The concept of aPDT is based on  
64 the principle that positively charged photosensitizers (PS) attach to the negatively  
65 charged cell walls of pathogens with subsequent killing upon activation of the PS by  
66 light of an appropriate wavelength and reactive oxygen species photogeneration <sup>8</sup>.  
67 The absorption of light by the PS leads to a transition of the excited PS molecule into  
68 its triplet excited state, from which there are two general reaction mechanisms for  
69 letting the PS regain its ground state: In type I mechanism, charge is transferred to a

70 substrate or molecular oxygen with emergence of reactive oxygen species (ROS) like  
71 hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) or oxygen radicals like superoxide ions ( $\text{O}_2^{\bullet-}$ ) and free  
72 hydroxyl radicals ( $\text{HO}^\bullet$ ), which are formed via Fenton-like reactions involving  $\text{H}_2\text{O}_2$ .  
73 In contrast, in type II mechanism, energy – but no charge – is transferred directly to  
74 molecular oxygen with formation of the highly reactive singlet oxygen ( $^1\text{O}_2$ )<sup>9,10</sup>. Due  
75 to its topical application form, aPDT may be a superior antimicrobial approach for  
76 treatment of localized infections on mucosal or dermal surfaces and consequently  
77 may be used in dentistry and dermatology.

78 Recently, our group introduced SAPYR (**1**) as a new class of PS based on a  
79 phenalen-1-one structure (Fig. 1), which exhibits a  $^1\text{O}_2$  quantum yield  $\Phi_\Delta$  close to  
80 unity ( $\Phi_\Delta = 0.99$ ) and showed pronounced antimicrobial efficacy against planktonic  
81 bacteria<sup>11</sup> as well as against monospecies and polyspecies biofilms<sup>12</sup>. The novel PS  
82 proved to be highly effective even upon illumination with a non-optimized light  
83 source.

84 In the present study, we evaluate a set of derivatives (Fig. 1) based on a phenalen-1-  
85 one structure (**6**), whereby the effect of the nature of the cationic substituents in the  
86 phenalen-1-one derivatives on the antimicrobial photodynamic efficacy is studied.

87

88 **Fig. 1. Chemical structures.** Reference-PS SAPYR (**1**), novel phenalen-1-  
89 one derivatives (**2**), (**3**), (**4**) and SAGUA (**5**) and basic structure phenalen-1-  
90 one (**6**).

91

92

93 Different determinants are crucial for effective interaction with the negative charges  
94 on a bacterial cell surface such as bulk, geometry and pKa-value. In addition, the

95 binding may be supplemented by H-bonding or  $\pi$ - $\pi$ -interaction. We wanted to have a  
96 closer look on such effects in phenalen-1-one derivatives.

97 Therefore, we compared SAPYR (**1**), which is equipped with a pyridinium moiety and  
98 serves as a reference PS, to compounds carrying a primary ammonium (**2**) or a  
99 secondary ammonium group (**3**), respectively. In addition, a cyclohexyl-substituted  
100 analog (**4**) for covering more lipophilic quaternary cations and a permanently  
101 positively charged guanidinium derivative (**5**; SAGUA) are examined.

102 As oral and dermal infections represent a superior field for clinical application of  
103 aPDT, due to their localized nature, the antimicrobial photodynamic efficacy of these  
104 new set of compounds is tested against planktonic cultures of oral and dermal key  
105 pathogens: Gram-positive *Streptococcus mutans* (SM), *Enterococcus faecalis* (EF),  
106 *Actinomyces naeslundii* (AN), *Staphylococcus aureus* (SA) and Gram-negative  
107 *Escherichia coli* (EC).

108 The aim of this study is (i) to evaluate this new set of compounds based on a  
109 phenalen-1-one structure regarding their antimicrobial photodynamic efficacy, (ii) to  
110 deduce a structure activity relationship concerning the effect of the nature of their  
111 cationic substituents on the antimicrobial efficacy and (iii) to study the efficacy at low  
112 light dose conditions using an optimized illumination device.

## 113 **Materials and Methods**

### 114 **General materials and methods**

115 Commercial reagents and starting materials were purchased from Acros Organics  
116 (U.S.), TCI Germany (Germany), Fluka (Germany), Merck (Germany), Frontier  
117 Scientific (U.S.) or Sigma-Aldrich (Switzerland) and used without further purification.

118 The dry solvents acetone, dichloromethane, dimethylsulfoxide and  
119 dimethylformamide were purchased from Roth, Germany (RotiDry Sept) or Sigma-  
120 Aldrich, Switzerland (puriss., absolute), stored over molecular sieves under nitrogen  
121 and were used as received.

122 Thin layer chromatography (TLC) analyses were performed on silica gel 60 F-254  
123 with 0.2 mm layer thickness and detection via UV light at 254 nm / 366 nm or through  
124 staining with ninhydrin in ethanol. Flash column chromatography was performed on  
125 Merck silica gel (Si 60 40-63  $\mu\text{m}$ ) either manually or on a Biotage® solera™ flash  
126 purification system. Column chromatography was performed on silica gel (70–230  
127 mesh) from Merck.

128 Melting points were measured on a SRS melting point apparatus (MPA100 Opti Melt)  
129 and are not corrected.

130 Nuclear Magnetic Resonance (NMR) spectra were recorded on Bruker Avance 300  
131 ( $^1\text{H}$  300.13 MHz,  $^{13}\text{C}$  75.47 MHz, T = 300 K), Bruker Avance 400 ( $^1\text{H}$  400.13 MHz,  
132  $^{13}\text{C}$  100.61 MHz, T = 300 K), Bruker Avance 600 ( $^1\text{H}$  600.13 MHz,  $^{13}\text{C}$  150.92 MHz, T  
133 = 300 K) and Bruker Avance III 600 Kryo ( $^1\text{H}$  600.25 MHz,  $^{13}\text{C}$  150.95 MHz, T = 300  
134 K) instruments. The chemical shifts are reported in  $\delta$ [ppm] relative to external  
135 standards (solvent residual peak). The spectra were analyzed by first order, the  
136 coupling constants  $J$  are given in Hertz [Hz]. Characterization of the signals: s =  
137 singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, psq =

138 pseudo quintet, dd = double doublet, dt = doublet of triplets, ddd = double double  
139 doublet. Integration is determined as the relative number of atoms. Assignment of  
140 signals in  $^{13}\text{C}$ -spectra was determined with 2D-spectroscopy (COSY, HSQC and  
141 HMBC) or DEPT technique (pulse angle:  $135^\circ$ ) and given as (+) for  $\text{CH}_3$  or CH, (-)  
142 for  $\text{CH}_2$  and ( $\text{C}_q$ ) for quaternary  $\text{C}_q$ . Error of reported values: chemical shift 0.01 ppm  
143 ( $^1\text{H}$  NMR) and 0.1 ppm ( $^{13}\text{C}$  NMR), coupling constant  $J$  0.1 Hz. The solvents used for  
144 the measurements are reported for each spectrum.

145 Infrared spectroscopy was done for each compound. IR spectra were recorded with a  
146 Bio-Rad FT-IR-FTS 155 spectrometer. Fluorescence spectra were recorded on a  
147 'Cary Eclipse' fluorescence spectrophotometer and absorption spectra on a "Cary  
148 BIO 50" UV/VIS/NIR spectrometer from Varian. All measurements were performed in  
149 1 cm quartz cuvettes (Hellma) and UV-grade solvents (Baker or Merck) at  $25^\circ\text{C}$ .

150 Mass spectroscopy was done to detect the Mass spectra (MS) of all compounds. MS  
151 were recorded on Varian CH-5 (EI), Finnigan MAT95 (EI-, CI- and FAB-MS), Agilent  
152 Q-TOF 6540 UHD (ESI-MS, APCI-MS), Finnigan MAT SSQ 710 A (EI-MS, CI-MS) or  
153 Thermo Quest Finnigan TSQ 7000 (ES-MS, APCI-MS) spectrometer. Xenon serves  
154 as the ionization gas for FAB.


155

## 156 **Synthesis and purification of the compounds**

157 Substances **1** and **7** were prepared from (**6**) after literature known procedures (Figure  
158 2 & reference <sup>11</sup>). The purity of all synthesized compounds was determined by NMR  
159 spectroscopic methods (Bruker Avance 300, DMSO- $d_6$ ) and HPLC-MS confirming a  
160 purity of > 97%.

161

### 162 ***2-Aminomethyl-1H-phenalen-1-one Hydrochloride (2)***



163

164 In a dry flask with moisture protection dried methanol (20 mL) was stirred in an  
165 icebath. A steady stream of ammonia gas was introduced into the flask and bubbled  
166 through the solution for 30 min. 2-Chloromethyl-1*H*-phenalen-1-one (**7**) (228 mg, 1  
167 mmol) in methanol/DMF (dry, 6 mL, 1:1) was added drop wise to the icecold solution  
168 over a period of 10 min. Introduction of ammonia was continued as a slow stream  
169 bubbling through the vigorously stirring solution for 3h, whilst reaching room  
170 temperature (a yellow precipitate begins to form, TLC control shows complete  
171 conversion of the starting material). Stirring at room temperature was continued for  
172 10h, the solvent and excess ammonia was removed in a stream of nitrogen (fume  
173 hood! The N<sub>2</sub>-purged ammonia vapor is absorbed in a separate flask by diluted  
174 sulfuric acid). The residue was dissolved in the minimum amount of DMF and  
175 precipitated by the addition of diethylether. The product was settled with the aid of a  
176 centrifuge (60 min, 4400 rpm, 0°C) and the supernatant was discarded. The  
177 precipitate was re-suspended in diethylether, settled again and the supernatant was  
178 decanted off. The residue was dissolved in the minimum amount of  
179 dichloromethane/ethanol 8:1 and precipitated with diethylether again. The product  
180 was settled with the aid of a centrifuge (60 min, 4400 rpm, 0°C) and the supernatant  
181 was discarded. The precipitate was re-suspended in diethylether, settled again and  
182 the supernatant was decanted off. This washing step was repeated twice. Yellow  
183 powder, 46 % of theoretical.


184

185 **<sup>1</sup>H-NMR** (300 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 8.58 (d, J = 6.7 Hz, 1H), 8.56 (d, J = 6.6  
 186 Hz, 1H), 8.52 (m, 3H), 8.32 (d, J = 7.6 Hz, 1H), 8.21 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H),  
 187 7.95 (t, J = 7.6 Hz, 1H), 7.79 (t, J = 7.7 Hz, 1H), 3.97 (s, 2H). - **<sup>13</sup>C-NMR** (75 MHz,  
 188 DMSO-d<sub>6</sub>): δ[ppm] = 183.08 (q), 141.69 (+), 135.93 (+), 133.00 (+), 131.72 (+),  
 189 130.33 (q), 127.87 (q), 127.59 (q), 127.38 (+), 126.25 (q), 126.05 (q), 37.51 (-); - **MS**  
 190 (ESI-MS, CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 10 mmol NH<sub>4</sub>OAc): m/z (%) = 210.1 (MH<sup>+</sup>, 100%), 193.1  
 191 (M<sup>+</sup> - NH<sub>3</sub>, 31%); - **IR** (neat): ν[cm<sup>-1</sup>] = 3123, 3037, 2809, 2018, 1754, 1638, 1597,  
 192 1566, 1399, 1260, 910, 783, 682; - **MW (molecular weight)** = 210.26 + 35.45 g/mol;  
 193 - **MF (molecular formula)** = C<sub>14</sub>H<sub>12</sub>NOCl.

194

195

196 ***N*-Methyl-*N*-(1-oxo-1*H*-phenalen-2-yl)methanaminium chloride (3)**



197

198 2-Chloromethyl-1*H*-phenalen-1-one (**7**) (113 mg, 0.5 mmol) in methanol (10 mL) was  
 199 added drop wise to an icecold solution of methylamine in methanol (40 mL, 10 %)  
 200 over a period of 1h. After 30 h of vigorous stirring at room temperature, the solvent  
 201 and excess methylamine was removed in a stream of nitrogen (fume hood; The N<sub>2</sub>-  
 202 purged methylamine vapor is absorbed in a separate flask by diluted sulfuric acid).  
 203 The residue was dissolved in the minimum amount of DCM/ethanol 4:1 and  
 204 precipitated by the addition of diethylether. The product was settled with the aid of a  
 205 centrifuge (60 min, 4400 rpm, 0°C) and the supernatant was discarded. This step  
 206 was repeated one more time.

207 The precipitate was re-suspended in diethylether, settled again and the supernatant  
 208 was decanted off. This washing step was repeated twice. Yellow-brownish powder,  
 209 78 % of theoretical (101 mg, 0.39 mmol).


210

211 **<sup>1</sup>H-NMR** (300 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 9.01 (m, app. bs, 1H), 8.57 (d, J = 7.4 Hz,  
 212 1H), 8.52 (d, J = 7.6 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 8.29 (s, 1H), 8.09 (d, J = 8.2  
 213 Hz, 1H), 7.95 (t, J = 7.5 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 4.06 (s, 2H), 2.60 (s, 3H). -  
 214 **<sup>13</sup>C-NMR** (75 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 183.17 (q), 143.30 (+), 135.99 (+), 133.30  
 215 (+), 133.02 (+), 131.65 (q), 130.43 (+), 130.08 (q), 127.86 (q), 127.61 (+), 127.38 (+),  
 216 126.36 (q), 126.00 (q), 46.39 (-), 32.47 (+); - **MS** (ESI-MS, CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 10 mmol  
 217 NH<sub>4</sub>OAc): m/z (%) = 224.1 (MH<sup>+</sup>, 100%); - **IR** (neat): ν[cm<sup>-1</sup>] = 3384, 2989, 2953,  
 218 2742, 2669, 2569, 2481, 2435, 1621, 1567, 1509, 1464, 1404, 1375, 1349, 1257,  
 219 1230, 1197, 1116, 1020, 952, 906, 849, 778, 597, 571; - **MW** = 224.28 + 35.45 g/mol;  
 220 - **MF** = C<sub>15</sub>H<sub>14</sub>NOCl.

221

222

223 **1-((1-oxo-1H-phenalen-2-yl)methyl)-1-methyl-2,3-di(tert-**  
 224 **butoxycarbonyl)guanidin (8)** (conditions adapted from <sup>13</sup>)



225

226 In an oven-dried, 25 mL round-bottomed flask *N,N*-di-Boc-*N*<sup>m</sup>-triflylguanidine (0.41 g,  
 227 1.05 mmol) is dissolved in DCM (10 mL). Triethylamine (0.3 g, 0.39 mL, 3 mmol) is  
 228 added slowly at 2-5°C under moisture protection. Compound **3** (130 mg, 0.5 mmol)

229 was added in one portion. After 5 h stirring at room temperature, the mixture is  
230 diluted with dichloromethane (30 mL) and transferred to a separatory funnel. The  
231 organic layer is washed with aqueous potassium hydrogen sulfate (10 mL, 5%),  
232 saturated sodium bicarbonate solution (10 mL) and brine (20 mL), dried over MgSO<sub>4</sub>,  
233 filtered and concentrated under reduced pressure. The raw material was purified by  
234 column chromatography with acetone/petroleum ether 1:2 to afford the product as  
235 bright yellow powder in nearly quantitative yield (0.21 g). For further purification, the  
236 material was dissolved in acetone (1 mL) and precipitated with petroleum ether (14  
237 mL). The precipitate was filtered off and the filter cake was washed with petroleum  
238 ether.

239


240 **<sup>1</sup>H-NMR** (300 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 9.70 (bs, 1H), 8.57 (d, J = 7.3 Hz, 1H), 8.50  
241 (d, J = 7.8 Hz, 1H), 8.29 (d, J = 8.1 Hz, 1H), 8.02 – 7.96 (m, 1H), 7.94 (t, J = 7.6 Hz,  
242 1H), 7.86 (s, 1H), 7.77 (t, J = 7.6 Hz, 1H), 4.50 (s, 2H), 2.97 (s, 3H), 1.39 (s, 9H),  
243 1.35 (s, 9H). - **<sup>13</sup>C-NMR** (75 MHz, CDCl<sub>3</sub>): δ[ppm] = 185.15 (q), 135.45 (+), 133.66  
244 (q), 132.25 (+), 131.93 (q), 131.18 (+), 128.96 (q), 127.30 (+), 127.07 (q), 126.87 (+),  
245 80.40 (q), 50.00 (-), 31.22 (+), 28.24 (+), 27.98 (+); - **MS** (ESI-MS, CH<sub>2</sub>Cl<sub>2</sub>/MeOH +  
246 10 mmol NH<sub>4</sub>OAc): m/z (%) = 466.1 (MH<sup>+</sup>, 100%); - **IR** (neat): ν[cm<sup>-1</sup>] = 3160, 2971,  
247 2927, 1746, 1677, 1588, 1511, 1452, 1391, 1364, 1300, 1250, 1221, 1141, 1067,  
248 1024, 974, 951, 903, 843, 786, 743, 683, 621, 538; - **MW** = 465.53 g/mol; - **MF** =  
249 C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>5</sub>

250

251

252 ***1-((1-oxo-1H-phenalen-2-yl)methyl)-1-methyl-guanidiniumchloride***

253 **(5)**



254

255 Compound **8** (200 mg, 0.45 mmol) was dissolved in dichloromethane (20 mL, dried  
 256 over CaCl<sub>2</sub>). A saturated solution of hydrogen chloride in diethylether (2 mL) was  
 257 added dropwise. After stirring for 4 h at room temperature under moisture protection,  
 258 the suspension was partitioned between four blue caps and diethylether was added  
 259 to a total volume of 15 mL per cap. The product was settled with the aid of a  
 260 centrifuge (60 min, 4400 rpm, 0°C) and the supernatant was discarded. The  
 261 precipitate was re-suspended in diethylether, settled again and the supernatant was  
 262 decanted off. This washing step was repeated once using diethylether. Afterwards  
 263 the product was dried at reduced pressure to give 130 mg of yellow powder.

264


265 **<sup>1</sup>H-NMR** (300 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 8.60 – 8.47 (m, 2H), 8.29 (d, J = 7.4 Hz,  
 266 1H), 8.13 (d, J = 7.4 Hz, 1H), 7.94 (t, J = 8.0 Hz, 1H), 7.84 – 7.73 (m, 2H), 7.50 (m,  
 267 app. bs, 4H), 4.49 (s, 2H), 3.06 (s, 3H). - **<sup>13</sup>C-NMR** (75 MHz, DMSO-d<sub>6</sub>): δ[ppm] =  
 268 183.66 (q), 157.14 (q), 137.68 (+), 135.75 (+), 132.64 (+), 132.19 (+), 131.60 (q),  
 269 130.02 (+), 128.19 (q), 127.44 (+), 127.28 (+), 126.48 (q), 126.10 (q), 49.39 (-), 36.22  
 270 (+); - **MS** (ESI-MS, CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 10 mmol NH<sub>4</sub>OAc): m/z (%) = 266.1 (MH<sup>+</sup>,  
 271 100%); - **IR** (neat): ν[cm<sup>-1</sup>] = 3303, 3203, 3125, 1631, 1592, 1563, 1528, 1454, 1402,  
 272 1363, 1259, 1199, 1114, 1020, 967, 812, 783, 646, 603; - **MW** = 266.3 + 35.45 =  
 273 301.75 g/mol; - **MF** = C<sub>16</sub>H<sub>16</sub>N<sub>3</sub>OCl

274

275

276 **1-methyl-1-((1-oxo-1H-phenalen-2-yl)methyl)piperidinium chloride**

277 **(4)**



278

279 2-Chloromethyl-1H-phenalen-1-one (**7**) (230 mg, 1 mmol) was dissolved in DMF (4  
 280 mL). N-methylpiperidin (1.98 g, 2.42 mL, 20 mmol) was added and the solution was  
 281 stirred 30 h at room temperature. After cooling to room temperature, diethylether (45  
 282 mL) was added, the precipitate was settled with the aid of a centrifuge and the  
 283 supernatant was discarded. The product was dissolved in methanol (2 mL),  
 284 precipitated with diethylether (28 mL) and settled again. The precipitate was re-  
 285 suspended in and washed with diethylether several times.

286 Afterwards the product was dried at reduced pressure. If necessary, the product is  
 287 purified by column chromatography with silica gel using chloroform/methanol 6:1 →  
 288 5:1 as the eluent. The product is a dark yellow-greenish powder, 166 mg (51 %)

289

290 **<sup>1</sup>H-NMR** (300 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 8.60 – 8.51 (m, 2H), 8.47 (s, 1H), 8.41 –  
 291 8.35 (m, 1H), 8.18 (dd, J = 7.1, 0.7 Hz, 1H), 7.98 – 7.91 (m, 1H), 7.82 (dd, J = 8.2,  
 292 7.1 Hz, 1H), 4.59 (s, 2H), 3.47 (m, 4H), 3.08 (s, 3H), 1.95 – 1.79 (m, 4H), 1.68 – 1.46  
 293 (m, 2H). - **<sup>13</sup>C-NMR** (75 MHz, DMSO-d<sub>6</sub>): δ[ppm] = 183.31 (q), 149.34 (+), 135.68  
 294 (+), 134.01 (+), 133.53 (+), 131.51 (q), 130.71 (+), 128.21 (q), 127.50 (+), 127.22 (+),  
 295 126.72 (q), 126.59 (q), 125.99 (q), 60.58 (-), 60.00 (-), 46.18 (+), 20.50 (-), 19.48 (-); -  
 296 **MS** (ESI-MS, CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 10 mmol NH<sub>4</sub>OAc): m/z (%) = 292.2 (M<sup>+</sup>, 100%); - **IR**  
 297 (neat): ν[cm<sup>-1</sup>] = 3016, 2944, 2869, 1634, 1579, 1510, 1469, 1403, 1360, 1255, 1227,

298 1191, 1126, 1078, 1030, 938, 875, 831, 774; - **MW** = 292.4 + 35.45 = 327.85 g/mol; -

299 **MF** = C<sub>20</sub>H<sub>22</sub>NOCl

300

### 301 **Photophysical characterization**

302 The <sup>1</sup>O<sub>2</sub> quantum yields  $\Phi_{\Delta}$  of all compounds were determined using SAPYR (**1**) with  
303 a  $\Phi_{\Delta}$  = 0.99 as a reference PS (synthesized as described earlier <sup>11</sup> and according to  
304 patent No. WO/2012/113860 <sup>14</sup> in the Department of Organic Chemistry, University of  
305 Regensburg, Germany; purity: 98%) employing the methodology described  
306 elsewhere <sup>11,12</sup>. Briefly, singlet oxygen luminescence signals were recorded at 1270  
307 nm with a high sensitive photomultiplier system (R5509-42, Hamamatsu Photonics,  
308 Hamamatsu, Japan) and an ultrafast multiscaler (P7889, FAST ComTec,  
309 Oberhaching, Germany). For spectral resolution, luminescence was detected at  
310 wavelengths from 1150 to 1350 nm by using interference filters in front of the  
311 photomultiplier. All compounds were excited at a wavelength of 405 nm generated by  
312 a tunable laser system (NT 242-SH/SFG, Ekspla, Vilnius, Lithuania). For  
313 determination of the <sup>1</sup>O<sub>2</sub> quantum yields of each compound the absorbed energies of  
314 all compounds were compared with their emitted singlet oxygen luminescence at  
315 1270 nm in regard with the reference photosensitizer SAPYR, as described recently  
316 <sup>11,12</sup>.

317 For determination of the photostability of the tested compounds, solutions (100  $\mu$ M, 2  
318 mL) of **1** – **5** were irradiated for 10 min with 10 mW at 400 nm, applying a total  
319 irradiation energy of 6 J. The solutions were magnetically stirred while irradiation and  
320 their transmissions were measured before and after irradiation.

321 Absorption spectra for determination of pH-stability and estimation of the octanol-  
322 water-partition coefficients were recorded on a Varian Cary BIO 50 UV/vis/NIR  
323 spectrometer with temperature control using 1 cm quartz cuvettes (Hellma) and

324 Uvasol solvents (Merck, Baker, or Acros) or Millipore water (18 M $\Omega$ ). Fluorescence  
325 measurements were performed with UV-grade solvents (Baker or Merck) in 1 cm  
326 quartz cuvettes (Hellma) and recorded on a Varian “Cary Eclipse” fluorescence  
327 spectrophotometer with temperature control.

328

### 329 **Light source**

330 Illumination of all samples was performed for 60 s using a blue light emitting  
331 prototype containing a neon tube (BlueV, Medizintechnik Herbert Waldmann GmbH  
332 & Co. KG, Villingen-Schwenningen, Germany). An intensity of 20 mW/cm<sup>2</sup> at the  
333 level of the samples were measured and total light dose of 1.2 J/cm<sup>2</sup> was applied.  
334 Intensity was measured with a thermal low-power sensor (Nova 30 A-P-SH, Ophir-  
335 Spiricon, North Logan, UT) and the emission spectrum of the light source was  
336 recorded by means of a monochromator with a CCD detection system (SPEX 232,  
337 HORIBA Jobin Yvon, Longjumeau Cedex, France). The well plates containing the  
338 samples ( )were illuminated from below with direct contact to the bottom of the wells,  
339 wherefore diffusion of light due to surface tensions in the samples could be excluded.

340

### 341 **Bacterial culture**

342 Five reference strains, *Streptococcus mutans* (*SM*; ATCC 25175), *Enterococcus*  
343 *faecalis* (*EF*; ATCC 29212), *Actinomyces naeslundii* (*AN*; T14V), *Staphylococcus*  
344 *aureus* (*SA*; ATCC 25923) and *Escherichia coli* (*EC*; ATCC 25922) were used in this  
345 study.

346 The respective culture media were Brain Heart Infusion Broth (BHI broth; Sigma-  
347 Aldrich, St. Louis, MO) for *SM*, *EF* and *AN* as well as Mueller Hinton Broth (Sigma-  
348 Aldrich, St. Louis, MO) for *SA* and *EC*. All strains were grown over-night at 37°C on

349 an orbital shaker under aerobic conditions in order to obtain bacteria in the stationary  
350 growth phase. After that period, bacteria were harvested by centrifugation (3000 rpm,  
351 10 min; Megafuge 1.0, Heraeus Sepatech, Osterode, Germany) and re-suspended in  
352 sterile water. Consequently samples were diluted to yield an optical density (OD) of  
353 0.6 measured at 600 nm by means of a photospectrometer (DU<sup>®</sup> 640, Beckman-  
354 Coulter, Krefeld, Germany), which corresponds to a number of approximately 10<sup>7</sup>  
355 bacteria per ml. These suspensions were used for aPDT-experiments.

356

### 357 **Photodynamic inactivation of bacteria**

358 Bacterial cell suspensions with OD = 0.6 were mixed in 96-well flat-bottom, colorless  
359 microtiter plates (Corning Costar<sup>®</sup>, Corning, NY) one-to-one either with 100 µL H<sub>2</sub>O  
360 or with 100 µL PS obtaining final PS-concentrations of 0 µM, 1 µM, 5 µM, 10 µM, 16  
361 µM, 25 µM or 100 µM, respectively. Immediately after a 10 s incubation period  
362 samples were irradiated for 60 s with the BlueV Prototype (20 mW/cm<sup>2</sup>) or  
363 maintained in the dark during the same period. Irradiation with the BlueV Prototype  
364 ensured consistent irradiation and equal intensity over a whole 96-well microtiter  
365 plate. Illumination was done from the bottom side of the 96-well plates to avoid  
366 diffusion of light due to surface tensions in the samples. Serial tenfold dilutions (10<sup>-1</sup>  
367 to 10<sup>-6</sup>) were prepared in BHI Broth (*SM*, *EF*, *AN*) or Mueller Hinton Broth (*SA*, *EC*)  
368 and aliquots (3 x 20 µL) were plated on agar plates, as described earlier<sup>15</sup>. Mueller-  
369 Hinton-Agar plates were used for *SM*, *EF*, *SA* and *EC* and blood agar plates for *AN*  
370 (provided by the Institute of Medical Microbiology and Hygiene, University Medical  
371 Center Regensburg, Germany). Plates were incubated aerobically at 37°C for 24 h  
372 (*EF*, *SA* and *EC*) or 48 h (*SM*, *AN*); then colony forming units (CFU) were counted.  
373 Six independent experiments with three sub-samples per each experimental group  
374 were performed.

375

376 **Data analysis**

377 For all aPDT experiments, CFU counts of experimental data were related to  
378 untreated controls (L-, 0  $\mu$ M, 100%) and expressed as relative survival (% CFU). The  
379 results comprise data from at least six independent experiments with three sub-  
380 samples per each experimental group, whereby CFU counts of a sample were  
381 calculated as the median CFU counts of the three corresponding sub-samples.

382 This obtained data was plotted as bar charts depicting medians and 25-75%  
383 quantiles, where horizontal and dashed lines represent reductions of 3  $\log_{10}$  steps  
384 (99.9%; antimicrobial effect) and 5  $\log_{10}$  steps (99.999%; disinfecting effect),  
385 respectively. A reduction of at least  $\geq 3 \log_{10}$  of viable median numbers of bacteria  
386 was declared as biologically relevant with regard to the guidelines of hand hygiene <sup>16</sup>.

387  $\log_{10}$  reduction rates were deduced for each PS from each bacterial species at each  
388 PS concentration and were presented in a table (see table 2). A reduction of less  
389 than 1  $\log_{10}$  step was defined as virtually no antibacterial efficacy.

390 For each PS and each bacterial species relative survival values were fitted  
391 (TableCurve 2D, Systat Software Inc., San Jose, CA, USA) including dose-response-  
392 functions. From resulting four parameter Sigmoid curves ( $r^2 \geq 0.83$ ) the PS  
393 concentrations (including 95% confidence limits) necessary to achieve a reduction  
394 rate of 5  $\log_{10}$  steps (EC 5  $\log_{10}$ ) (99.999%; disinfecting effect <sup>16</sup>) were derived and  
395 depicted as a bar chart.

396 For each PS median (25-75% Quantiles) of EC 5  $\log_{10}$  values over all bacterial  
397 species were calculated, depicted as a bar chart, and statistically rated using the  
398 Tukey-interval method. Data analysis, except fitting, was performed using SPSS for  
399 Windows, version 20 (SPSS Inc., Chicago, IL, USA).

## 400 Results

### 401 Preparation of photosensitizers

402 The PS presented in this study are water-soluble dyes based on a phenalen-1-one  
403 structure (**6**). All derivatives were synthesized with a purity of > 97%, controlled by  
404 NMR spectroscopy and HPLC-MS. Phenalen-1-one (**6**) was first converted to its  
405 chloromethylated analog (**7**). Derivatives **1** – **4** are obtained by conversion of (**7**) in  
406 methanol (**2**, **3**) or N,N-dimethylformamide (DMF) (**1**, **4**) with excess amine at slightly  
407 elevated temperature in good to excellent yields. Purification was achieved by  
408 precipitation with diethylether and re-precipitation from ethanol with diethylether, until  
409 the UV/Vis spectra showed constant absorption. The compound with the pyridinium  
410 moiety (**1**, SAPYR) was prepared in a similar manner as described earlier <sup>11</sup> (Fig. 2).

411

#### 412 Fig. 2. Scheme of the synthesis of phenalen-1-one PS

413 **A. Synthesis of phenalene-1-one derivatives 1 - 4.** Conditions: a) HCl<sub>(aq)</sub>,  
414 HOAc, H<sub>3</sub>PO<sub>4</sub>, HCHO, 120°C, over night, 36 %; b) pyridine, DMF (*N,N*-  
415 *Dimethylformamide*), room temperature, over night, 50°C, 5 h, 83 %; c) MeOH,  
416 amine, room temperature, over night, 50°C, 2 – 10 h, 60 – 75 %, d) DMF, *N*-  
417 methyl-piperidine, room temperature, over night, 50°C, 2 – 10 h, 78 %.

418 **B. Synthesis of phenalen-1-one derivative SAGUA (5).** Conditions: a) *N,N'*-  
419 di-(tert-butoxycarbonyl)-*N''*-triflylguanidine, DCM (dichloromethane) (adapted  
420 from <sup>13</sup>), triethylamine, 0°C, then room temperature for 4 h, 88 %; b) HCl in  
421 Et<sub>2</sub>O, DCM, room temperature, 6 h, 50°C, 5 h, 96 %.

422

423 Starting from (2), (5) was prepared by reaction with *N,N'*-di-(tert-butoxycarbonyl)-*N''*-  
424 triflylguanidine in dichloromethane (DCM) and subsequent deprotection with HCl in  
425 diethylether in excellent overall yield (Fig. 3).

426

## 427 **Photophysical characterization**

428 For all compounds 2 – 5 singlet oxygen quantum yields  $\Phi_{\Delta}$  could be estimated in a  
429 similar range compared to the reference PS SAPYR (1) ( $\Phi_{\Delta} = 0.99$ )<sup>12</sup>. The emission  
430 spectrum of the light source (BlueV) and the absorption spectrum of SAPYR have an  
431 overlap at wavelengths longer than 400 nm (Fig. 3).

432

433 **Fig. 3. Absorption and emission spectra.** Absorption coefficient of SAPYR  
434 (1) (red dotted line) plotted with the emitted energy of the light source BlueV  
435 within 60 s (blue solid line).

436

437 Fig. 4 shows the results of the photostability measurements of SAGUA (5). No  
438 photobleaching could be observed under the conditions used here (irradiation at 400  
439 nm with 10 mW for 10 min, corresponding to 6 J laser energy). Likewise, when using  
440 the same conditions, no photobleaching of compounds 1 – 4 could be observed (for  
441 details please see electronic supplementary information file).

442

443 **Fig. 4. Photostability measurements of SAGUA (5).** The solid blue  
444 spectrum shows the absorption before irradiation, while the red dotted  
445 spectrum shows absorption after irradiation at 400 nm with 10 mW for 10 min,  
446 corresponding to 6 J laser energy. SAGUA (5) shows no photobleaching under  
447 the conditions used.

448

449 Physical characterization data is summarized in Table 1. The polarity of compounds  
450 **1 – 5** was estimated by measuring the partition coefficient. Distribution between  
451 water and n-octanol of  $1 \times 10^{-4}$  mol of each compound (**1 – 5**) was measured by UV/Vis  
452 spectroscopy after 20 minutes of stirring at room temperature.

453 As compounds **2** and **3** can be deprotonated in water, their partition coefficient was  
454 also measured using 10 mM acetate buffer at pH 4.4. The  $pK_b$  values of both  
455 compounds were obtained by pH-titration and were found to be 4.8 for (**2**) and 4.4 for  
456 (**3**), which is similar to already published data of benzylamine ( $pK_b = 4.65$ )<sup>17</sup>.





457 The pH stability of SAGUA (**5**) was determined by recording UV/Vis spectra in  
458 buffered aqueous solutions at different pH values (from pH 2 to pH 12) after  
459 incubation for 30 minutes. SAGUA (**5**) shows excellent stability in acidic medium  
460 (down to pH = 2), but decomposes slowly in alkaline solutions with pH > 10 (for  
461 UV/Vis spectra analysis please see electronic supplementary information file). In  
462 comparison to the other phenalen-1-one derivatives, e.g. SAPYR (**1**), which starts to  
463 decompose at pH > 9<sup>11</sup>, SAGUA (**5**) is slightly more stable at high pH values.

464 UV/Vis spectra of SAGUA (**5**) were recorded at different concentrations and showed  
465 no differences up to 1 mM concentration (for details please see electronic  
466 supplementary information file). Thus, aggregation can be neglected below the  
467 millimolar range (< 1 mM) and has not to be considered for our biological studies.

468

469

Table 1. Physical parameters of the phenalen-1-one derivatives.

Compound	 Residue R =	$\lambda_{\max}$ absorption [nm] <sup>(a)</sup>	$\lambda_{\max}$ emission [nm]	Singlet oxygen quantum yield $\Phi_{\Delta}$ <sup>(b)</sup>	octanol / water coefficient log D <sup>(c) (d)</sup>
SAPYR (1)		363 – 410 <sup>11</sup>	489 ± 5 <sup>11</sup>	0.99 ± 0.05 <sup>11</sup>	- 1.3 <sup>11</sup>
(2)		360 – 412	486 ± 5	0.89 ± 0.05	- 0.3 / - 1.1 <sup>(c)</sup>
(3)		362 – 415	487 ± 5	0.98 ± 0.05	- 0.1 / - 1.0 <sup>(c)</sup>
(4)		360 – 418	492 ± 5	0.92 ± 0.05	- 1.2
SAGUA (5)		361 – 414	488 ± 5	0.86 ± 0.05	- 1.1

470

471

Conditions: at 25 °C, in Millipore water.

472

(a) all compounds show a broad absorption maximum in this region, which cannot be resolved in distinct maxima; the spectra were collected in air-equilibrated solution.

473

474

(b) the  $^1\text{O}_2$  quantum yield  $\Phi_{\Delta}$  was determined using SAPYR (1) with a  $\Phi_{\Delta}$  = 0.99 as a reference PS (synthesized as described earlier<sup>11</sup>; purity: 98%);

475

476

(c) values measured by partition between 10 mM acetate buffer at pH 4.4 and n-octanol ( $\text{pK}_b$  = 4.8 for (2) and 4.4 for (3)).

477

478

(d) for compounds 1, 4 and 5 log D = log P, as only one species is present; at the given pH values the guanidinium group in (5) is protonated ( $\text{pK}_a$  = 12)

479

## 481 **Photodynamic inactivation of bacteria**

482 aPDT was performed against oral and dermal pathogens *Streptococcus mutans*  
483 (*SM*), *Enterococcus faecalis* (*EF*), *Actinomyces naeslundii* (*AN*), *Staphylococcus*  
484 *aureus* (*SA*) and *Escherichia coli* (*EC*) using the phenalen-1-one compounds **1 – 5** as  
485 PS. Bacterial suspensions were incubated for 10 s with the PS in concentrations  
486 ranging from 1 to 100  $\mu\text{M}$  followed by irradiation for 60 s with a blue light emitting  
487 prototype (BlueV, Waldmann, Villingen-Schwenningen, Germany; intensity at  
488 sample-level: 20  $\text{mW}/\text{cm}^2$ ; light dose: 1.2  $\text{J}/\text{cm}^2$ ). Colony forming units (CFU) were  
489 evaluated according to the methodology described by Miles, Misra and Irwin<sup>15</sup>.  
490 Untreated control groups without PS and without light irradiation (L-, 0  $\mu\text{M}$ ), which  
491 exhibited CFU in a range between  $10^6$  and  $5 \times 10^7$ , were set as 100% in order to  
492 calculate relative survival rates. In all cases, neither treatment with PS alone nor with  
493 light alone led to any decrease of CFU compared to untreated control groups (L-, 0  
494  $\mu\text{M}$ ) (Fig.5). Fig. 5 exemplarily depicts the photodynamic inactivation rates of  
495 compounds **1 – 5** against Gram-positive *EF* and Gram-negative *EC* (results for *SM*,  
496 *AN* and *SA* are shown in electronic supplementary information file). The medians on  
497 or below the black horizontal line represents  $\geq 99.9\%$  efficacy of photodynamic  
498 bacteria killing, whereas the black dotted horizontal line represents  $\geq 99.999\%$  killing  
499 efficacy, both compared to matching untreated control groups (bacteria only, neither  
500 treatment with PS nor with light). In general, a median-reduction of at least 3  $\log_{10}$   
501 steps of viable bacteria is stated as biologically relevant with regard to the guidelines  
502 of hand hygiene<sup>16</sup>. Therefore, the differences seen in the bacterial inactivation of *EF*  
503 and *EC* is within the experimental accuracy (Fig. 5). All other differences detected  
504 are discussed later within the manuscript. For all PS the photodynamic inactivation  
505 rates arise with increasing concentrations as dose-response curves.

506

507 **Fig. 5. Photodynamic inactivation of Gram-positive *E. faecalis* (A) and**  
508 **Gram-negative *E. coli* (B) with phenalen-1-one derivatives 1 – 5.** aPDT  
509 results of phenalen-1-one derivatives (1 – 5) upon light activation (L+; 1.2  
510 J/cm<sup>2</sup>, samples were irradiated) against Gram-positive *E. faecalis* and Gram-  
511 negative *E. coli* shown as relative survival rates with untreated controls (L-, 0  
512 μM, without irradiation) being set as 100%. Horizontal and dashed lines depict  
513 reductions of 3 log<sub>10</sub> steps (99.9%; antimicrobial effect) and 5 log<sub>10</sub> steps  
514 (99.999%; disinfectant effect), respectively.  
515 (CFU: colony forming units; red: SAPYR (1); green: (2); yellow: (3); blue: (4);  
516 pink: SAGUA (5)).

517

518 At a concentration of 16 μM all PS showed reductions of ≥ 5 log<sub>10</sub> steps following  
519 light activation regardless of the respective bacterial species (Table 2). At 10 μM all  
520 PS exhibited reductions of ≥ 3 log<sub>10</sub> steps. (2) and SAGUA (5) even reached  
521 inactivation rates of ≥ 6 log<sub>10</sub> steps at a concentration of 10 μM after light activation  
522 against all bacterial species, whereby SAGUA (5) even showed reductions of ≥ 3  
523 log<sub>10</sub> steps at a concentration of 5 μM against all Gram-positive pathogens (*SM*, *EF*,  
524 *AN* and *SA*).

525

526

Table 2. aPDT killing rates of all phenalen-1-one derivatives.

PS	Bacteria	log <sub>10</sub> reduction rates					
		PS concentrations [ $\mu$ M]*					
		0	1	5	10	16	25
<b>SAPYR (1)</b>	SM	- <sup>a</sup>	-	-	$\geq 6$	$\geq 6$	$\geq 6$
	EF	-	-	$\geq 2$	$\geq 5$	$\geq 6$	$\geq 6$
	AN	-	-	$\geq 2$	$\geq 6$	$\geq 6$	$\geq 6$
	SA	-	-	$\geq 1$	$\geq 6$	$\geq 6$	$\geq 6$
	EC	-	-	$\geq 1$	$\geq 6$	$\geq 6$	$\geq 6$
<b>(2)</b>	SM	-	-	$\geq 1$	$\geq 6$	$\geq 6$	$\geq 6$
	EF	-	-	-	$\geq 6$	$\geq 6$	$\geq 6$
	AN	-	-	$\geq 2$	$\geq 6$	$\geq 6$	$\geq 6$
	SA	-	-	$\geq 1$	$\geq 6$	$\geq 6$	$\geq 6$
	EC	-	-	$\geq 2$	$\geq 6$	$\geq 6$	$\geq 6$
<b>(3)</b>	SM	-	-	-	$\geq 6$	$\geq 6$	$\geq 6$
	EF	-	-	-	$\geq 3$	$\geq 6$	$\geq 6$
	AN	-	-	-	$\geq 6$	$\geq 6$	$\geq 6$
	SA	-	-	-	$\geq 6$	$\geq 5$	$\geq 6$
	EC	-	-	$\geq 1$	$\geq 3$	$\geq 6$	$\geq 6$
<b>(4)</b>	SM	-	-	$\geq 1$	$\geq 5$	$\geq 6$	$\geq 6$
	EF	-	-	-	$\geq 3$	$\geq 6$	$\geq 6$
	AN	-	-	$\geq 1$	$\geq 6$	$\geq 6$	$\geq 6$
	SA	-	$\geq 1$	$\geq 4$	$\geq 6$	$\geq 6$	$\geq 6$
	EC	-	-	$\geq 1$	$\geq 3$	$\geq 6$	$\geq 6$
<b>SAGUA (5)</b>	SM	-	-	$\geq 6$	$\geq 6$	$\geq 6$	$\geq 6$
	EF	-	-	$\geq 3$	$\geq 6$	$\geq 6$	$\geq 6$
	AN	-	-	$\geq 6$	$\geq 6$	$\geq 6$	$\geq 6$
	SA	-	$\geq 1$	$\geq 6$	$\geq 6$	$\geq 6$	$\geq 6$
	EC	-	-	$\geq 2$	$\geq 6$	$\geq 6$	$\geq 6$

527

528

529

530

\*Photodynamic inactivation rates of compounds **1** – **5** against all bacterial species investigated in this study upon light activation (1.2 J/cm<sup>2</sup>).

(SM – *Streptococcus mutans*; EF – *Enterococcus faecalis*; AN – *Actinomyces*

531 *naeslundii*; SA – *Staphylococcus aureus*; EC – *Escherichia coli*)  
532 <sup>a</sup>: - indicates < 1 log<sub>10</sub> step reduction of CFU, which was defined as virtually no  
533 antibacterial photodynamic efficacy. Thresholds for evaluation of antibacterial  
534 efficacy were inactivation rates of ≥ 3 log<sub>10</sub> steps (99.9%; antibacterial effect,  
535 light grey) and ≥ 5 log<sub>10</sub> steps (99.999%; disinfectant effect, dark grey).

536

537

538 In order to calculate the minimal effective concentrations (EC 5 log<sub>10</sub>) being  
539 necessary for a respective compound to achieve a photodynamic inactivation rate of  
540 5 log<sub>10</sub> steps (99.999% of bacteria killing, disinfecting effect) (Fig. 6), CFU-reduction  
541 rates of aPDT groups for each bacterial species were fitted. For facilitating the  
542 comparison of compound **2** – **5** with the reference PS SAPYR (**1**), medians of EC 5  
543 log<sub>10</sub> concentrations of each compound over all bacteria were calculated (Fig. 6B).

544

545 **Fig. 6. Effective concentrations for 5 log<sub>10</sub> inactivation.**

546 **A:** Effective concentrations (95% confidence limits) of compounds **1** - **5**  
547 against every bacteria tested, which were necessary to reach inactivation  
548 rates of 5 log<sub>10</sub> steps of CFU (99.999%; disinfectant effect) upon light  
549 activation (1.2 J/cm<sup>2</sup>) (red: SM – *Streptococcus mutans*; green: EF –  
550 *Enterococcus faecalis*; yellow: AN – *Actinomyces naeslundii*; blue: SA –  
551 *Staphylococcus aureus*; pink: EC – *Escherichia coli*).

552 **B:** Median values (25-75% Quantiles) of effective concentrations of  
553 compounds **1** - **5** of all bacteria tested, which were necessary to reach  
554 inactivation rates of 5 log<sub>10</sub> steps of CFU (99.999%; disinfectant effect) upon  
555 light activation (grey: median of all bacteria).

556

557 Consequently, the following ranking could be established: Compared to SAPYR (**1**)  
558 (8.1  $\mu\text{M}$ ), the EC 5  $\log_{10}$  of **2** (7.9  $\mu\text{M}$ ) was in a similar range, whereas SAGUA (**5**)  
559 (5.6  $\mu\text{M}$ ) was distinctly more effective. In contrast, **3** (11.1  $\mu\text{M}$ ) and **4** (11.4  $\mu\text{M}$ ) were  
560 distinctly less effective (Fig. 6B). According to the Tukey-interval method, only  
561 SAGUA (**5**) was found significantly different from **3** and **4**, respectively.

## 562 Discussion

563 Aim of this study was to evaluate the impact of alterations of the cationic charged  
564 anchoring groups in phenalen-1-one PS on their antimicrobial photodynamic efficacy  
565 since it is well known that already small differences either in the structure or in the  
566 physicochemical properties of substituents of PS can change their antimicrobial  
567 potency <sup>11</sup>. Photodynamic efficacy of phenalen-1-one PS was evaluated against  
568 planktonic cultures of oral and dermal key pathogens *SM*, *EF*, *AN*, *SA* and *EC* (with  
569 *EC* being a representative of Gram-negatives).

570 SAPYR (**1**), which is equipped with a pyridinium-methyl substituent, was used as a  
571 reference PS for comparison. For this compound, pronounced inactivation rates  
572 against planktonic bacteria <sup>11</sup> as well as against monospecies and polyspecies  
573 biofilms formed by oral key pathogens <sup>12</sup> have already been demonstrated. The  
574 newly synthesized derivatives carry as cationic substituents a primary ammonium ion  
575 (**2**), a secondary ammonium ion (**3**), a piperidinium group (**4**) or a permanently  
576 positively charged guanidinium group (**5**; SAGUA).

577 The whole range of steric demand is covered in this series with the primary and  
578 secondary ammonium groups in **2** and **3** being small cations and the pyridinium  
579 group in SAPYR (**1**) being planar, concentrating its quaternary positively charged  
580 character on the nitrogen atom (Fig. 7A). The quaternary cation in **4** is also  
581 concentrated on the nitrogen atom, but the piperidinium ring is a folded group  
582 consisting of sp<sup>3</sup> carbon centers with a considerably larger steric demand than a  
583 pyridinium unit <sup>18</sup> (Fig. 7A). Due to the fast tautomerism of the double bond between  
584 the nitrogen atoms the guanidinium group in SAGUA (**5**) represents a planar  
585 positively charged disk.

586

587 **Fig. 7.**

588 **A:** Illustration of the steric demand of the substituents in phenalen-1-one  
589 derivatives SAPYR (**1**), **4** and SAGUA (**5**); atom colours: red = oxygen, blue =  
590 nitrogen, white = hydrogen, grey = carbon.

591 **B:** Illustrations of the binding of phenalen-1-one derivatives SAPYR (**1**), **4** and  
592 SAGUA (**5**) to glutamate on the cell surface of bacteria. SAGUA (**5**) shows  
593 bidentate and directional hydrogen bonds in addition to the cationic charge  
594 attraction, exhibited by all positive charged moieties.

595

596 As fluctuations of pH values are omnipresent in a cellular environment, permanent  
597 charged moieties are very advantageous for the electrostatic attachment of the PS to  
598 bacterial cell surfaces. This is featured by the very alkaline guanidinium ion (pKa ~  
599 12) in SAGUA (**5**) and the quaternary ammonium i.e. pyridinium cations in SAPYR  
600 (**1**) and **4**.

601 Compound SAGUA (**5**) was found to be the most effective derivative. The  
602 guanidinium group is planar and a permanently charged cation (pKa ~ 12). The  
603 nature of this positively charged group may improve the attachment of the PS to the  
604 cell walls of pathogens. No alkyl or aryl substituents shield the strong and permanent  
605 charge. In addition, guanidinium groups can establish hydrogen bonds to phosphate  
606 and carboxylate groups<sup>19,20</sup>, which may improve the binding to target groups, e.g. to  
607 bacterial cell walls (Fig. 7B). Furthermore, the combination of the lipophilic  
608 chromophore and the guanidinium group may improve cell penetration, as it is known  
609 for example for arginine rich peptides<sup>21</sup>. In contrast, too hydrophilic molecules may  
610 be “washed away” more easily by the surrounding water, thus never reaching a  
611 critical amount of PS for good photodynamic efficacy.

612 When comparing these compounds regarding the antibacterial photodynamic  
613 efficacy, the reference PS SAPYR (**1**) was found to be less effective than SAGUA  
614 (**5**). The median threshold concentration needed for achieving an inactivation rate of  
615  $\geq 5 \log_{10}$  was 8.1  $\mu\text{M}$  for SAPYR (**1**) vs 5.6  $\mu\text{M}$  of SAGUA (**5**) (Fig. 5).

616 In contrast compound **4**, which can be seen as a structural analog to SAPYR (**1**) with  
617 a completely hydrogenated substituent, was the least effective derivative. Compound  
618 **4** is similar in its lipophilicity to SAPYR (**1**); its minor efficacy however may be  
619 attributed to the substantially higher steric demand of the piperidinium residue. This  
620 bulky group may hinder the charge to establish a close and strong electrostatic  
621 interaction with the negatively charged bacterial cell surface.

622 Looking at compound **2** and **3**, which are similar to each other regarding the nature of  
623 their charged moieties, their steric demand and their lipophilicity, these two  
624 derivatives demonstrated different efficacy rates: Considering compound **3**, the  
625 median threshold concentration being necessary for a  $\geq 5 \log_{10}$  inactivation was  
626 similar to **4** (11.1  $\mu\text{M}$  compared to 11.4  $\mu\text{M}$ ), whereas for compound **2** similar or even  
627 lower concentrations than for SAPYR (**1**) were sufficient to achieve a  $\geq 5 \log_{10}$   
628 reduction (7.9  $\mu\text{M}$ ). This may be explained by the protonation equilibria of these  
629 charged moieties in the rather complex environment present at the bacterial surface.  
630 The conditions that are existent in an aqueous solution are not analogous to the  
631 conditions prevailing at the surface of bacterial cells or in their cell membranes. Thus,  
632 even small differences in the pKa value may have drastic effects, resulting in a lower  
633 local concentration of **3** and the reduced antibacterial photodynamic efficacy  
634 observed. On the surface of a bacterial cell, negative charges predominate over  
635 positive, which results in an increased effective pKa value. Inside the membrane  
636 different conditions dominate: In this milieu of low dielectric character charged  
637 molecules are in a state of higher energy. In particular, small ions like hydroxonium

638 are particularly affected by this, whereas the effect is less drastic for the larger PS  
639 molecules. Therefore, the effective pKa value is reduced and the hydroxonium  
640 concentration must be far higher compared to the exterior to protonate the phenalen-  
641 1-one derivative in the membrane. It is conceivable, that both compounds **2** and **3**  
642 constantly switch between the bacterial membrane and the outside.

643 Recently we demonstrated the antibacterial photodynamic properties of SAPYR (**1**)  
644 against planktonic cultures of Gram-positive *SM*, *EF*, *AN* and Gram-negative  
645 *Aggregatibacter actinomycetemcomitans* using a dental light curing unit (bluephase®  
646 C8, Ivoclar-vivadent, Schaan, Liechtenstein) as a light source <sup>11</sup>. Although the  
647 overlap of the emission of this light source with the absorption of SAPYR (**1**) was only  
648 about 5%, pronounced photodynamic inactivation rates could be achieved due to the  
649 high power of the light source (output power:  $1360 \pm 50$  mW/cm<sup>2</sup>; power at level of  
650 the samples:  $1260 \pm 50$  mW/cm<sup>2</sup>); thereby, an irradiation for 120 s (light dose: 150  
651 J/cm<sup>2</sup>) of SAPYR (**1**) at a concentration of 5  $\mu$ M was adequate to reduce CFU of *EF*  
652 and *SM* by  $\geq 6 \log_{10}$ . For achieving the same results for *AN* with SAPYR (**1**) at 5  $\mu$ M  
653 an irradiation period of 40 s (light dose: 50 J/cm<sup>2</sup>) was sufficient <sup>11</sup>. However, for  
654 *Aggregatibacter actinomycetemcomitans* aPDT results were distorted by a strong  
655 light toxicity of this species towards irradiation with blue light <sup>11</sup>, which was  
656 substantiated in a subsequent study by the presence of endogenous porphyrines and  
657 flavins in *Aggregatibacter actinomycetemcomitans*, which can act as PS <sup>22</sup>.

658 In the present study we employed a light source with an optimized emission  
659 spectrum in order to be able to reduce the illumination energy, but to conserve the  
660 pronounced efficacy. This is an important point since it is well known that blue light  
661 (in particular, at wavelengths shorter than 450 nm) can be detrimental towards  
662 human skin cells at high light doses <sup>23</sup>. Furthermore, it is well known that high-power  
663 dental curing lamps can cause damage to oral soft tissue due to heat generation <sup>24</sup>.

664 In contrast, the prototype blue light source (BlueV) reaches a power at sample level  
665 of 20 mW/cm<sup>2</sup>, which leads to a light dose of 1.2 J/cm<sup>2</sup> while irradiating for 60 s only.  
666 The match (integral of the convolution) of the absorption spectra of SAPYR (**1**) and  
667 emission spectra of the BlueV (Fig. 2) can be seen as fourfold compared to that  
668 found with the Bluephase® C8 <sup>11</sup>. Considering inactivation of *SM* with 10 μM of  
669 SAPYR (**1**), in the former study a ≥ 6 log<sub>10</sub> inactivation could only be reached upon  
670 irradiation for 40 s applying a light dose of 50 J/cm<sup>2</sup>, whereas in the present study we  
671 were able to get the same efficacy in a virtually equivalent time of 60 s with a light  
672 dose of only 1.2 J/cm<sup>2</sup>. Consequently, due to the better adaptation of the light source  
673 to the absorption spectrum of SAPYR (**1**), we were able to reduce the light dose in a  
674 pronounced manner (up to 60-fold), while high efficacy rates for photodynamic  
675 inactivation were conserved.

676 All in all, in this study a structure activity relationship of phenalen-1-one derivatives **1**  
677 – **5** concerning the effect of the nature of their cationic substituents on the  
678 antimicrobial efficacy could be successfully deduced. Due to optimization of the light  
679 source the efficacy of aPDT with phenalen-1-ones could be improved.

## 680 Conclusion

681 The structure activity relationship deduced in the present study shows that a  
682 permanently positive-charged moiety in combination with a slightly lipophilic  
683 character ( $\log P < 1$ ) as a substituent of a phenalen-1-one PS seems to be a criterion  
684 for good photodynamic efficacy. The combination of both a permanently positive-  
685 charged moiety of a PS and the possibility of a PS to the formation of strong,  
686 directional hydrogen bonds towards cell walls of pathogens seems to be even more  
687 beneficial for the antimicrobial action.

688 The results of this study clearly demonstrate that the functional substituent of  
689 guanidinium enhances the photodynamic antimicrobial efficacy substantially ( $\geq 6$   
690  $\log_{10}$ ; disinfecting effect), inactivating both dental and dermal key pathogens within 60  
691 s applying a light dose of only  $1.2 \text{ J/cm}^2$ . The use of an optimized light source  
692 enables a fast and effective eradication of pathogens at low light doses (up to 60-fold  
693 less as demonstrated earlier<sup>14</sup>) and ensures protection of surrounding tissue.

694 With its singlet oxygen quantum yield close to unity and the high photostability,  
695 SAGUA (**5**) encourages further research on optimizing handling modalities of aPDT  
696 with phenalen-1-one derivatives, e.g. designing an appropriate formulation for clinical  
697 application of SAGUA (**5**) in order to reach pathogens on dermal or mucosal  
698 surfaces. In addition, SAGUA (**5**) may be useful as a promising tool for industrial and  
699 clinical purposes where repeatable treatments are necessary and savings in time are  
700 critical to achieve efficient inactivation of bacteria. Consequently, SAGUA (**5**) may  
701 also serve as a lead candidate for development of even more potent phenalen-1-one  
702 PS in the future.

## 703 **Acknowledgement**

704 Ewa Kowalewski and Jana Schiller are gratefully acknowledged for excellent  
705 technical assistance. Fabian Cieplik is funded by the University Medical Center  
706 Regensburg within the ReForM A program. Johannes Regensburger is funded by a  
707 grant of the German Research Foundation (DFG-RE-3323/2-1).

708 All authors declare that they have no conflict of interest.

709

710

711

712

## 713 **Author contributions**

714 Conceived and designed the experiments: TM AS KAH FC WB.

715 Performed the experiments: IT JR AS.

716 Analyzed the data: KAH IT FC JR TM AS.

717 Contributed reagents/materials/ analysis tools: AS JR KAH.

718 Wrote the paper: IT FC AS TM KAH LT WB.

719

720 **References**

- 721 1 G. M. Rossolini and E. Mantengoli, *Clin. Microbiol. Infect.*, 2008, **14 Suppl 6**, 2–  
722 8.
- 723 2 T. Yamamoto, Y. Tamura and T. Yokota, *Antimicrob. Agents Chemother.*, 1988,  
724 **32**, 932–935.
- 725 3 S. P. Yazdankhah, A. A. Scheie, E. A. Høiby, B.-T. Lunestad, E. Heir, T. Ø.  
726 Fotland, K. Naterstad and H. Kruse, *Microb. Drug Resist.*, 2006, **12**, 83–90.
- 727 4 G. Jori and G. Roncucci, *Adv. Clin. Exp. Med.*, 2006, **15**, 421–426.
- 728 5 E. Alves, M. A. Faustino, M. G. Neves, A. Cunha, J. Tome and A. Almeida,  
729 *Future Med. Chem.*, 2014, **6**, 141–164.
- 730 6 T. Maisch, *Lasers Med. Sci.*, 2007, **22**, 83–91.
- 731 7 T. Maisch, S. Hackbarth, J. Regensburger, A. Felgenträger, W. Bäumlner, M.  
732 Landthaler and B. Röder, *J. Dtsch. Dermatol. Ges.*, 2011, **9**, 360–366.
- 733 8 E. Alves, L. Costa, C. M. Carvalho, J. P. Tomé, M. A. Faustino, M. G. Neves, A.  
734 C. Tomé, J. A. Cavaleiro, A. Cunha and A. Almeida, *BMC Microbiol.*, 2009, **9**,  
735 70.
- 736 9 M. Wainwright, *J. Antimicrob. Chemother.*, 1998, **42**, 13–28.
- 737 10 T. Maisch, J. Baier, B. Franz, M. Maier, M. Landthaler, R.-M. Szeimies and W.  
738 Bäumlner, *Proc. Natl. Acad. Sci. U.S.A.*, 2007, **104**, 7223–7228.
- 739 11 A. Späth, C. Leibl, F. Cieplik, K. Lehner, J. Regensburger, K.-A. Hiller, W.  
740 Bäumlner, G. Schmalz and T. Maisch, *J. Med. Chem.*, 2014, **57**, 5157–5168.
- 741 12 F. Cieplik, A. Späth, J. Regensburger, A. Gollmer, L. Tabenski, K.-A. Hiller, W.  
742 Bäumlner, T. Maisch and G. Schmalz, *Free Radic. Biol. Med.*, 2013, **65**, 477–487.
- 743 13 T. J. Baker, M. Tomioka and M. Goodman, *Org. Synth.*, 2002.
- 744 14 WO/2012/113860, *WO Patent WO/2012/113860*, 2012.
- 745 15 A. A. Miles, S. S. Misra and J. O. Irwin, *J. Hyg. (London)*, 1938, **38**, 732–749.
- 746 16 J. M. Boyce and D. Pittet, *Infect. Control Hosp. Epidemiol.*, 2002, **23**, 3–40.
- 747 17 Z. Rappoport and M. Frankel, *CRC handbook of tables for organic compound*  
748 *identification*, 1967.
- 749 18 S. E. Boiadjev and D. A. Lightner, *Chirality*, 2000, **12**, 204–215.
- 750 19 A. Späth and B. König, *Tetrahedron*, 2010, **66**, 1859–1873.
- 751 20 A. Späth and B. König, *Tetrahedron*, 2010, **66**, 6019–6025.
- 752 21 O. M. New and D. Dolphin, *Eur. J. Org. Chem.*, 2009, **2009**, 2675–2686.
- 753 22 F. Cieplik, A. Späth, C. Leibl, A. Gollmer, J. Regensburger, L. Tabenski, K.-A.  
754 Hiller, T. Maisch and G. Schmalz, *Clin. Oral Investig.*, 2014, **18**, 1763–1769.
- 755 23 J. Liebmann, M. Born and V. Kolb-Bachofen, *J. Invest. Dermatol.*, 2010, **130**,  
756 259–269.
- 757 24 T. J. Spranley, M. Winkler, J. Dagate, D. Oncale and E. Strother, *Gen. Dent.*,  
758 2012, **60**, e210–4.
- 759
- 760

761 **Electronic supplementary information (ESI)**

762 **ESI file.** Experimental details, materials and methods relating to synthesis and  
763 characterization, selected NMR spectra, UV-Vis data concerning aggregation and  
764 stability and relative survival rates against all bacteria.




Figure 1. Chemical structures. Reference-PS SAPYR (1), novel phenalen-1-one derivatives (2; SA-PN-02b), (3; SA-PN-02c), (4; SA-PN-08b) and (5; SAGUA) and basic structure phenalen-1-one (6)  
159x45mm (182 x 182 DPI)




Fig. 2. Scheme of the synthesis of phenalene-1-one PS  
 A. Synthesis of phenalene-1-one derivatives 1 - 4. Conditions: a) HCl(aq), HOAc, H<sub>3</sub>PO<sub>4</sub>, HCHO, 120°C, over night, 36 %; b) pyridine, DMF, room temperature, over night, 50°C, 5 h, 83 %; c) MeOH, amine, room temperature, over night, 50°C, 2 - 10 h, 60 - 75 %, d) DMF, N-methyl-piperidine, room temperature, over night, 50°C, 2 - 10 h, 78 %.  
 159x252mm (150 x 150 DPI)




Fig. 3 Absorption and emission spectra.  
Absorption coefficient of SAPYR (1) (red dotted line) plotted with the emitted energy of the light source BlueV within 60 s (blue solid line).  
291x153mm (150 x 150 DPI)






Figure 4. Photostability measurements of SAGUA (5). The solid blue spectrum shows the absorption before irradiation, while the red dotted spectrum shows absorption after irradiation at 400 nm with 10 mW for 10 min, corresponding to 6 J laser energy. SAGUA (5) shows no photobleaching under the conditions used.  
290x180mm (200 x 200 DPI)



242x358mm (600 x 600 DPI)




Fig. 6 Effective concentrations for 5 log<sub>10</sub> inactivation.

A: Effective concentrations (95% confidence limits) of compounds 1 - 5 against every bacteria tested, which were necessary to reach inactivation rates of 5 log<sub>10</sub> steps of CFU (99.999%; disinfectant effect) upon light activation (1.2 J/cm<sup>2</sup>) (red: SM – *Streptococcus mutans*; green: EF – *Enterococcus faecalis*; yellow: AN – *Actinomyces naeslundii*; blue: SA – *Staphylococcus aureus*; pink: EC – *Escherichia coli*).

B: Median values (25-75% Quantiles) of effective concentrations of compounds 1 - 5 of all bacteria tested, which were necessary to reach inactivation rates of 5 log<sub>10</sub> steps of CFU (99.999%; disinfectant effect) upon light activation (grey: median of all bacteria).

296x209mm (300 x 300 DPI)




**A****B**

Figure 7. Scheme of the steric demand and hydrogen bonds

A: Illustration of the steric demand of the substituents in phenalen-1-one derivatives SAPYR (1), 4 and SAGUA (5); atom colours: red = oxygen, blue = nitrogen, white = hydrogen, grey = carbon.  
 B: Illustrations of the binding of phenalen-1-one derivatives SAPYR (1), 4 and SAGUA (5) to glutamate on the cell surface of bacteria. SAGUA (5) shows bidentate and directional hydrogen bonds in addition to the cationic charge attraction, exhibited by all positive charged moieties.  
 215x272mm (300 x 300 DPI)



Graphical abstract.

SAGUA with its guanidinium moiety reaching a maximum efficacy of  $\geq 6$  log<sub>10</sub> steps of bacteria killing at a concentration of 10  $\mu\text{M}$  upon irradiation with blue light (20 mW/cm<sup>2</sup>) for 60 s (1.2 J/cm<sup>2</sup>) without exhibiting inherent dark toxicity.

127x60mm (300 x 300 DPI)